

- Osato, M., Asou, N., Okubo, T., Nishimura, S., Yamasaki, H., Era, T., Suzushima, H., Kawano, F., Matsuoka, R., Oka, H., Bae, S.C., Ito, Y. & Takatsuki, K. (1997) Myelomonoblastic leukaemia cells carrying the PEBP2 $\beta$ /MYH11 fusion gene are CD34+, c-KIT+ immature cells. *British Journal of Haematology*, **97**, 656–658.
- Peterson, L.F. & Zhang, D.E. (2004) The 8;21 translocation in leukemogenesis. *Oncogene*, **23**, 4255–4262.
- Ross, M.E., Mahfouz, R., Onciu, M., Liu, H.C., Zhou, X., Song, G., Shurtleff, S.A., Pounds, S., Cheng, C., Ma, J., Ribeiro, R.C., Rubnitz, J.E., Girtman, K., Williams, W.K., Raimondi, S.C., Liang, D.C., Shih, L.Y., Pui, C.H. & Downing, J.R. (2004) Gene expression profiling of pediatric acute myelogenous leukemia. *Blood*, **104**, 3679–3687.
- Schoch, C., Kohlmann, A., Schnittger, S., Brors, B., Dugas, M., Mergenthaler, S., Kern, W., Hiddemann, W., Eils, R. & Haferlach, T. (2002) Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America, **99**, 10008–10013.
- Shigesada, K., van de Sluis, B. & Liu, P.P. (2004) Mechanism of leukemogenesis by the inv(16) chimeric gene CBF $\beta$ /PEBP2 $\beta$ -MYY11. *Oncogene*, **23**, 4297–4307.
- Speck, N.A. & Gilliland, D.G. (2002) Core-binding factors in haematopoiesis and leukaemia. *Nature Reviews Cancer*, **2**, 502–513.
- Valk, P.J.M., Verhaak, R.G.W., Beijen, M.A., Erpelinck, C.A.J., van Doorn-Khosrovani, S.B.v.W., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van der Spek, P.J., Lowenberg, B. & Delwel, R. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. *The New England Journal of Medicine*, **350**, 1617–1628.
- Yagi, T., Morimoto, A., Eguchi, M., Hibi, S., Sako, M., Ishii, E., Mizutani, S., Imashuku, S., Ohki, M. & Ichikawa, H. (2003) Identification of a gene expression signature associated with pediatric AML prognosis. *Blood*, **102**, 1849–1856.
- Yergeau, D.A., Hetherington, C.J., Wang, Q., Zhang, P., Sharpe, A.H., Binder, M., Marin-Padilla, M., Tenen, D.G., Speck, N.A. & Zhang, D.E. (1997) Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. *Nature Genetics*, **15**, 303–306.
- Zhang, J., Kalkum, M., Yamamura, S., Chait, B.T. & Roeder, R.G. (2004) E protein silencing by the leukemogenic AML1-ETO fusion protein. *Science*, **305**, 1286–1289.

## Supplementary material

The following supplementary material is available for this article online:

**Fig S1.** (A) Schematic illustration of the gene extraction procedure. Test (G2 or G4) and reference (G1, G3 or G1 + G3 + G5) samples were subjected to pair-wise comparisons as indicated by the double-headed arrows. To extract G2-associated transcripts, comparison was made between G2 and G1 and between G2 and G1 + G3 + G5. Genes extracted by two rounds of comparison were defined as G2-associated. G4-associated transcripts were similarly extracted. Criteria of gene extraction were that average expression of test samples was significantly ( $P < 0.01$ ) greater than twofold increased or decreased compared with the reference samples. (B) Venn diagram comparison of transcripts extracted by the method described in A. The numbers of transcripts belonging to G2-associated highly expressed, G4-associated highly expressed, G2-associated low expression and G4-associated low expression transcripts are indicated. (C) Modification of the extraction procedure. The starting material was the genes shown in panel B, and each criterion defined in broken rectangles was applied to them. As a result, 3 common, 5 G2-specific and 26 G4-specific highly expressed transcripts, and 0 common, 10 G2-specific and 11 G4-specific low expression transcripts were reclassified. The numbers of transcripts shown in panels B and C represent numbers of probe sets.

**Table SI.** Fifty paediatric AML patients enrolled in this study

**Table SII.** Transcripts whose expression was modulated commonly in G2 and G4 and specifically to each.

This material is available as part of the online article from <http://www.blackwell-synergy.com>

# Extramedullary Infiltration at Diagnosis and Prognosis in Children With Acute Myelogenous Leukemia

Ryoji Kobayashi, MD,<sup>1\*</sup> Akio Tawa, MD,<sup>2</sup> Ryoji Hanada, MD,<sup>3</sup> Keizo Horibe, MD,<sup>4</sup>  
 Masahiro Tsuchida, MD,<sup>5</sup> Ichiro Tsukimoto, MD<sup>6</sup>  
 and Japanese childhood AML cooperative study group

**Background.** Extramedullary infiltration (EMI) is an occasional clinical symptom in childhood acute myelogenous leukemia (AML), but there is considerable controversy regarding the prognostic significance of EMI in AML. **Procedure.** We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in children. **Results.** Of 240 cases of de novo AML excluding children with Down syndrome and acute promyelocytic leukemia, 56 (23.3%) showed EMI at diagnosis. Patients with EMI had a higher initial WBC count and a higher proportion of M4/M5 morphological variants. The complete remission rate following induction chemotherapy was

lower in patients with EMI. However, the overall survival and event-free survival did not differ between patients with and without EMI. A detailed analysis showed that patients with EMI with a WBC count at diagnosis of over  $100 \times 10^9/L$  or infiltration into the central nervous system are likely to have a poor prognosis. **Conclusions.** CNS leukemia and EMI together with a WBC count of  $>100 \times 10^9/L$  at diagnosis of AML are high risk factors for relapse, and alternative treatment approaches for patients with these characteristics should be explored. *Pediatr Blood Cancer* 2007;48:393–398.  
 © 2006 Wiley-Liss, Inc.

**Key words:** AML; childhood; extramedullary infiltration

## INTRODUCTION

Acute myelogenous leukemia (AML) refers to a heterogeneous group of diseases, and AML patients may have distinct morphologic, cytochemical, immunophenotypic, and clinical characteristics. Extramedullary infiltration (EMI), which includes tumor nodules (myeloid or granulocytic sarcoma), skin infiltration (leukemia cutis), meningeal infiltration, gingival infiltration, or hepatosplenomegaly [1], has been reported to be more common in myelomonoblastic and monoblastic subtypes of AML (FAB M4 and M5) than in other morphological subgroups [2–8]. The prognostic importance of EMI is controversial, but the outcome of children with AML who initially present with EMI is generally thought to be poor [9–13], although several studies have suggested otherwise [2,14,15]. Using tailored treatment protocol for AML patients, which we refer to as AML99, we evaluated the incidence and prognostic significance of EMI in patients with AML.

## PATIENTS AND METHODS

Between January 2000 and December 2002, a total of 240 patients of less than 16 years of age with untreated AML excluding children with Down syndrome and acute promyelocytic leukemia were registered by the Japanese childhood AML cooperative study group. Of these patients, 128 were boys and 112 were girls. Morphology subtyping by the French–American–British (FAB) system was performed at the treating institutions. CNS leukemia was diagnosed on the basis of  $>5$  blast cells/ $\mu l$  in the CSF without blood contamination, and EMI was defined as leukemic infiltration in organs other than liver, spleen, and lymph nodes. Complete remission was defined as  $<5\%$  blast cells in the bone marrow,

normal hematopoiesis, the absence of blasts cells in the peripheral blood and disappearance of EMI. Relapse was defined as a return of leukemic blast cells in the bone marrow ( $>20\%$ ) and/or the return of EMI.

## Treatment Protocol

The chemotherapy regimens (AML99 protocol) are outlined in Figure 1, excluding those for children with Down syndrome and acute promyelocytic leukemia; the drug doses and schedules are shown in Table I. Patients of less than 2 years of age or with WBC counts of  $<100 \times 10^9/L$  were treated with induction A therapy (etoposide  $150 \text{ mg}/\text{m}^2$ , days 1–5; cytosine arabinoside  $200 \text{ mg}/\text{m}^2$ , days 6–12; mitoxantrone  $5 \text{ mg}/\text{m}^2$ , days 6–10), and those over 2 years of age with WBC counts of  $\geq 100 \times 10^9/L$  were treated with induction B therapy (etoposide  $100 \text{ mg}/\text{m}^2$ , days 1–3;  $200 \text{ mg}/\text{m}^2$ , days 11–13; cytosine arabinoside  $500 \text{ mg}/\text{m}^2$ , days 4–6 and days

<sup>1</sup>Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan; <sup>2</sup>Department of Pediatrics, Osaka National Hospital, Osaka, Japan; <sup>3</sup>Department of Hematology and Oncology, Saitama Children's Medical Center, Saitama, Japan; <sup>4</sup>Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; <sup>5</sup>Department of Pediatrics, Ibaraki Children's Hospital, Mito, Japan; <sup>6</sup>Department of Pediatrics, Toho University School of Medicine, Tokyo, Japan

Grant sponsor: Ministry of Health, Labor and Welfare, Japan.

\*Correspondence to: Dr. Ryoji Kobayashi, Department of Pediatrics, Hokkaido University Graduate School of Medicine North 15-West 7, Kitaku Sapporo 060-8638, Japan.

E-mail: r-koba@med.hokudai.ac.jp

Received 21 October 2005; Accepted 2 February 2006




Fig. 1. Schema of the AML99 Study.

11–13; idarubicin, 8 mg/m<sup>2</sup>, days 4–6). Patients with M3 marrow after induction A were treated with induction C (CA 500 mg/m<sup>2</sup> div, days 1–3, 8–10, IDA 8 mg/m<sup>2</sup> div, days 1–3, VP16 200 mg/m<sup>2</sup> div, days 8–10).

The AML99 study was planned to test the concept of risk-stratified treatment. Patients were stratified into three risk categories: low (inv(16), t(8;21) and WBC <50 × 10<sup>9</sup>/L; age <2 years old, without HR factors), high (–7, 5q–, Ph1, t(16;21), remission failure), and intermediate (neither low nor high risk). The basic framework of AML99 involved prospective enrollment of patients for risk-adapted therapy. Low risk (LR) patients were treated exclusively with chemotherapy regardless of the availability of a donor for HSCT, whereas all high-risk (HR) patients were treated with hematological stem cell transplantation (HSCT). Intermediate risk (IR) patients with an HLA-matched donor were treated with HSCT and those without a donor were treated with chemotherapy. Patients with Down syndrome and acute promyelocytic leukemia were treated using the AML99 Down protocol and AML99 M3 protocol, respectively. Determination of CR was made after induction therapy and course 1.

**Statistical Analysis**

A *t* test or chi-square test was used to compare patients with and without EMI. Analysis of overall survival and event-

free survival (EFS) were performed using the Kaplan–Meier method, with differences compared by log-rank test. Multivariate analysis stepwise regression was performed to explore the independent effects of variables that showed a significant influence in univariate analysis. Statistical analyses were performed using Dr. SPSS II for Windows (release 11.0.1J, SPSS Japan Inc.).

**RESULTS**

EMI was a complication in 56 of the 240 AML patients (23.3%). The presenting clinical and hematological features of patients with EMI are summarized and compared with those of patients without EMI in Table II. The median age in each group was not significantly different. Patients with EMI had a higher initial WBC count and a higher proportion of M4/M5 morphological variants (57.1 vs. 27.7%). Cytogenetically, patients with EMI had a higher population of inv16 and 11q23 abnormalities.

EMI was noted at a single site in 49 (87.5%) out of the 56 patients, whereas the remaining 7 patients (12.3%) had EMI at multiple sites. Among the patients with a single site of EMI, there were 13 cases of skin infiltration, 7 of gingival involvement, 7 of CNS leukemia, 5 of bone involvement, and 4 of orbital tumor. The seven patients with EMI at multiple

TABLE I. AML99 Study: Chemotherapy

Drugs	Dose/Route	Duration
Induction A		
VP16	150 mg/m <sup>2</sup> div	Days 1-5
CA	200 mg/m <sup>2</sup> div	Days 6-12
MIT	5 mg/m <sup>2</sup> div	Days 6-10
Triple it		Day 6
Induction B		
VP16	100 mg/m <sup>2</sup> div	Days 1-3
CA	500 mg/m <sup>2</sup> div	Days 4-6, 11-13
IDA	8 mg/m <sup>2</sup> div	Days 1-3
VP16	200 mg/m <sup>2</sup> div	Days 11-13
Triple it		Day 4
Induction C		
CA	500 mg/m <sup>2</sup> div	Days 1-3, 8-10
IDA	8 mg/m <sup>2</sup> div	Days 1-3
VP16	200 mg/m <sup>2</sup> div	Days 8-10
Triple it		Day 1
Course 1, 4		
VP16	100 mg/m <sup>2</sup> div	Days 1-5
CA	3 g/m <sup>2</sup> × 2 div	Days 1-3
IDA	10 mg/m <sup>2</sup> div	Day 1
triple it		Day 1
Course 2, 5H		
VP16	150 mg/m <sup>2</sup> div	Days 1-3
CA	200 mg/m <sup>2</sup> div	Days 4-8
MIT	5 mg/m <sup>2</sup> div	Days 4-6
Triple it		Day 1
Course 3, 5L		
VP16	100 mg/m <sup>2</sup> div	Days 1-5
CA	2 g/m <sup>2</sup> × 2 div	Days 1-5
Triple it		Day 1
Course 6		
VP16	200 mg/m <sup>2</sup>	Day 1-3, 8-10
CA	500 mg/m <sup>2</sup>	Day 1-3, 8-10
Triple it		Day 1

Triple it: under 1 y MTX 5 mg, CA 10 mg, HDC 10 mg; 1 y MTX 7.5 mg, CA 15 mg, HDC 15 mg; 2 y MTX 10 mg, CA 20 mg, HDC 20 mg; over 2 y MTX 12.5 mg, CA 25 mg, HDC 25 mg.  
 VP16, etoposide; CA, cytosine arabinoside; MIT, mitoxantrone; IDA, idarubicin; HDC, hydrocortisone; MTX, methotrexate.

sites included five cases of CNS leukemia, two of gingival involvement and two of testicular tumor. The presenting clinical and hematological features of patients in the EMI subgroups are shown in Table III. Although patients with CNS leukemia and multiple site infiltration were lower in age, the difference was not statistically significant. Cases with gingival involvement and skin infiltration showed a higher relative occurrence of monoblastic leukemia (M4/M5), and cases with EMI associated with CNS leukemia had a higher initial WBC count than with EMI at other sites.

In the 240 patients, the CR rate with induction chemotherapy was lower in patients with EMI (85.7 vs. 95.7%, *P* < 0.05). However, overall survival did not differ between patients with or without EMI (77.3 vs. 77.6%), and

although EFS was lower in patients with EMI, it was not statistically different from those without EMI (Table IV). In patients with EMI, those having WBC counts > 100 × 10<sup>9</sup>/L at diagnosis had a lower EFS, and the difference from EMI patients with lower WBC counts was statistically significant (*P* = 0.0052) (Fig. 2). EFS was also significantly lower in children with CNS leukemia, compared with those without EMI or with myeloblastoma.

DISCUSSION

The frequency of EMI at diagnosis in childhood AML varies in literature reports from 7 to 49%. The Children's Cancer Group (CCG) Study 2891 reported that extramedullary disease of any type occurred in 160 of 580 (27.6%) patients [16]. The Pediatric Oncology Group (POG) Study 8498 reported non-central nervous system extramedullary disease in 21 of 285 (7.4%) patients and Study 8821 reported 51 of 492 (10.4%) patients with this condition [9]. The BFM-78, BFM-83, and BFM-87 studies reported extramedullary organ involvement, defined as leukemic infiltration in organs other than the liver, spleen and central nervous system, in 33 of 84 (39.3%) patients younger than 2 years of age, and in 103 of 398 (25.9%) patients over 2 years of age [17].

The prognostic significance of EMI in AML at presentation and even the definition of EMI remain controversial; while some authors consider CNS leukemia or hepatosplenomegaly to be EMI, others do not [1,18]. The outcome of children with AML who initially present with EMI is generally thought to be poor [9-13], and gingival infiltration and CNS leukemia have been reported to be prognostic factors in childhood AML [10,19]. On the other hand, several reports suggest the presence of EMI at diagnosis has no significant effect on EFS [2,14,15]. In our study, patients with EMI accounted for 23.3% of the entire AML population, in concordance with past reports. Moreover, many patients with EMI had high WBC counts and cases of M4/M5. Although the complete remission rate of patients with EMI was lower than for other patients, this did not influence the survival rate and EFS, and hence did not change the prognosis. However, the prognosis of cases with CNS leukemia and high WBC counts was poor, and patients with EMI and WBC counts > 100 × 10<sup>9</sup>/L at diagnosis had a particularly low EFS.

In childhood AML, patients with high WBC counts have a poor prognosis [2,9]. We analyzed the prognosis of AML patients using two factors: the presence of EMI and a WBC count > 100 × 10<sup>9</sup>/L at diagnosis. Although patients with EMI and a WBC count > 100 × 10<sup>9</sup>/L at diagnosis had a lower EFS (23.8%), patients in the other three groups (i.e., those with EMI and a WBC count ≤ 100 × 10<sup>9</sup>/L; those without EMI and with a WBC count > 100 × 10<sup>9</sup>/L; and those without EMI and a WBC counts ≤ 100 × 10<sup>9</sup>/L) had

TABLE II. Comparison Between Patients With and Without EMI

	EMI (+) (n = 56)	EMI (-) (n = 184)	
Age (years)			
Median (range)	4.1 (7 d-15.4 y)	6.9 (2 m-15.8 y)	NS
Gender (M/F)	32/24	88/96	NS
WBC ( $\times 10^9/L$ )(range)	28.7 (2.5-365.0)	20.3 (0.8-621.0)	$P < 0.05$
FAB			
M0	2 (3.6%)	8 (4.3%)	NS
M1	10 (17.9%)	26 (14.1%)	NS
M2	11 (19.6%)	73 (39.7%)	$P < 0.05$
M4/M5	32 (57.1%)	51 (27.7%)	$P < 0.05$
M6	0 (0%)	3 (1.6%)	NS
M7	1 (1.8%)	19 (10.3%)	$P < 0.05$
Chromosome			
t(8;21)	11 (19.6%)	60 (32.6%)	NS
inv16	5 (8.9%)	7 (3.8%)	NS
11q23	19 (33.9%)	23 (12.5%)	$P < 0.05$
Induction therapy			
A	48 (85.7%)	166 (90.2%)	NS
B	8 (14.3%)	18 (9.8%)	NS
Complete remission	48 (85.7%)	176 (95.6%)	$P < 0.05$
HR	7 (12.5%)	18 (9.8%)	NS
IR	15 (26.8%)	77 (41.8%)	$P < 0.05$
LR	27 (48.2%)	83 (45.1%)	NS

TABLE III. Patient Characteristics in the EMI Subgroups and in Patients Without EMI

	No EMI	Myeloblastoma	Gingival infiltration	CNS leukemia	Skin infiltration	Multiple sites
Number of patients	184	22	7	7	13	7
Gender (M/F)	88/96	13/9	4/3	3/4	7/6	5/2
Age	6.90	4.87	6.90	1.87	6.14	1.87
<2 y	28	3	0	4	5	5
FAB						
M4/M5	51	8	6	3	11	4
Other	133	14	1	4	2	3
WBC( $\times 10^9/L$ )	20.3*	17.8*	84.0*	91.1*	55.4*	11.5


\* $P < 0.05$ .

Fig. 2. Kaplan-Meier estimate of event-free survival for patients with and without extramedullary infiltration at diagnosis. In patients with EMI, those having WBC counts  $>100 \times 10^9/L$  at diagnosis had a lower EFS compared of no EMI with WBC counts  $<100 \times 10^9/L$  ( $P = 0.0021$ ), no EMI with WBC counts  $\geq 100 \times 10^9/L$  ( $P = 0.0351$ ) and EMI with WBC counts  $<100 \times 10^9/L$  ( $P = 0.0303$ ).

a surprisingly similar EFS of 61.9, 63.6, and 62.4%, respectively. This suggests that the WBC count does not contribute to the prognosis of childhood AML in the absence of EMI. It is of note that the WBC count is often used as a factor for the selection of treatment, but our results suggest that WBC should not be used as a single prognostic factor. This reason is not clear. We conclude that CNS leukemia and EMI together with a WBC count of  $>100 \times 10^9/L$  at diagnosis of AML are HR factors for relapse and that alternative treatment approaches should be explored.

#### ACKNOWLEDGMENT

Principal investigators of Studies AML99: Ken Tabuchi, Hisato Kigasawa, Hiromasa Yabe, Hideki Nakayama, Kazuko Kudo, Kazuko Hamamoto, Masue Imaizumi, Akira Morimoto and Shigeru Tsuchiya. This work was supported in

TABLE IV. Three-Year Estimates of Event-Free Survival (EFS) in Patients With Acute Myelogenous Leukemia

Risk factor	No. of patients	Percentage EFS	P value
Gender			
Male	128	60.5 ± 4.4	0.9879
Female	112	60.2 ± 4.7	
Age			
<2	45	43.4 ± 7.6	0.0362
2-10	116	65.5 ± 4.4	
10-16	79	62.8 ± 5.5	
WBC count			
<50	175	61.7 ± 3.7	0.2806
50-100	29	65.5 ± 8.8	
>100	36	49.7 ± 8.4	
FAB			
M4/M5	83	54.0 ± 5.5	0.1668
Other	157	63.8 ± 3.9	
Cytogenetic findings			
t(8;21) or inv(16)	82	79.1 ± 4.5	0.0001
Other	158	50.6 ± 4.0	
EMI			
No EMI	184	62.5 ± 3.6	0.1174
EMI	56	53.3 ± 6.7	
EMI with WBC > 100 × 10 <sup>9</sup> /L	14	23.8 ± 12.9	0.0052
No EMI or EMI with WBC < 100 × 10 <sup>9</sup> /L	226	60.0 ± 3.5	
Myeloblastoma	22	72.7 ± 9.5	0.0467
Gingival infiltration	7	42.8 ± 18.7	
CNS leukemia	7	28.6 ± 17.1	
Skin infiltration	13	52.8 ± 14.1	
Multiple sites	7	—	

part by a Grant-in Aid for Clinical Cancer Research from the Ministry of Health, Labor and Welfare, Japan.

## REFERENCES

- Byrd JC, Edenfield WJ, Shields DJ, et al. Extramedullary myeloid cell tumors in acute non-lymphoblastic leukemia: A clinical review. *J Clin Oncol* 1995;13:1800-1816.
- Ravindranath Y, Steuber CP, Krishner J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group study. *J Clin Oncol* 1991;9:572-580.
- Luckit J, Bain B, Matutes E, et al. Teaching cases from the Royal Marsden and St Mary's Hospitals: An orbital mass in a young girl. *Leuk Lymphoma* 1998;28:621-2622.
- Vormoor J, Ritter J, Creutzig U, et al. Acute myelogenous leukemia in children under 2 years—experiences of the West German AML studies BFM-78, -83 and -87. *Br J Cancer* 1992;66:63-67.
- Van Wering ER, Kamps WA. Acute leukemia in infant. *Am J Pediatr Hematol Oncol* 1986;8:220-224.
- Pui CH, Kalwinsky DK, Schell MJ, et al. Acute non-lymphoblastic leukemia in infants: Clinical presentation and outcome. *J Clin Oncol* 1988;6:1008-1013.
- Ribeiro RC, Raimondi SC, Srivastava DK, et al. Prognostic factors for very young children with acute myeloid leukemia. *Blood* 1999;94:501a.
- Grier HE, Gelber RD, Camitta BM, et al. Prognostic factors in childhood acute myelogenous leukemia. *J Clin Oncol* 1987;5:1026-1032.
- Chang M, Raimondi SC, Ravindranath Y, et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. *Leukemia* 2000;14:1201-1207.
- Woods WG, Kobrinsky N, Buckley J, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Children's Cancer Group pilot study. *J Clin Oncol* 1993;11:1448-1457.
- Cavdar AO, Babacan E, Gozdasoglu S, et al. High risk subgroup of acute myelomonocytic leukemia (AMML) with orbito-ocular granulocytic sarcoma (OOGS) in Turkish children. Retrospective analysis of clinical, hematological, ultrastructural and therapeutic findings of thirty-three OOGS. *Acta Haematol* 1989;81:80-85.
- Hicsonmez G, Gurgey A, Zamani VP, et al. Poor prognosis in children with acute non-lymphoblastic leukemia in Turkey. *Am J Hematol* 1988;10:268-272.
- Grier HE, Gelber RD, Camitta BM, et al. Prognostic factors in childhood acute myelogenous leukemia. *J Clin Oncol* 1987;5:1026-1032.
- Amadori S, Testi AM, Arico M, et al. Prospective comparative study of bone marrow transplantation and post-remission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. *J Clin Oncol* 1993;11:1046-1054.

15. Bisschop MM, Revesz T, Bierings M, et al. Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia. *Leukemia* 2001;15:46–49.
16. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. *Blood* 1996;87:4979–4989.
17. Vormoor J, Ritter J, Creutzig U, et al. Acute myelogenous leukaemia in children under 2 years—experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group. *Br J Cancer* 1992;66:S63–S67.
18. Jenkin RD, Al-Shabanah M, Al-Nasser A, et al. Extramedullary myeloid tumors in children: The limited value of local treatment. *J Pediatr Hematol Oncol* 2000;22:34–40.
19. Hicsonmez G, Cetin M, Tuncer AM, et al. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: The effects of high-dose steroid treatment. *Leuk Res* 2004;28:25–34.

厚生労働科学研究費補助金  
がん臨床研究事業  
「小児造血器腫瘍の標準的治療法の確立に関する研究」

平成18年度

平成19年3月発行

発行者：堀部敬三（主任研究者）

事務局：独立行政法人国立病院機構

名古屋医療センター臨床研究センター内

〒460-0001 名古屋市中区三の丸4丁目1番1号

TEL:052-951-1111 FAX:052-963-5503

印刷所：サカイ印刷株式会社



